Marty Makary's FDA Tenure Leaves a Legacy of Weakness and Uncertainty

When it comes to public health, few roles are as critical as that of the Food and Drug Administration (FDA) Commissioner. The person in this position wields significant influence over the safety and efficacy of drugs, medical devices, and other health-related products. Over the past 25 years, I have closely followed the FDA’s operations, and it is with a heavy heart that I write: Marty Makary was the worst commissioner in that time.

Makary's tenure at the FDA lasted just over a year, but his impact has left deep scars on an agency already grappling with complex challenges. His approach to leadership was marked by a fundamental misunderstanding of the FDA’s role and responsibilities. This misalignment led to a series of decisions that weakened the agency’s standards, demoralized its staff, and raised serious concerns about future regulatory integrity.

Makary's appointment was initially met with optimism. He brought a background in surgery and public health, which seemed promising for an agency tasked with balancing scientific rigor and public safety. However, it quickly became apparent that Makary lacked the nuanced understanding required to navigate the intricate landscape of drug approval and regulation.

A Weakened Agency

One of the most significant issues during Makary’s tenure was the exodus of senior leadership. Many experienced officials either left voluntarily or were pushed out, creating a vacuum at the top levels of the FDA. This turnover not only disrupted ongoing projects but also eroded trust among employees and stakeholders. The loss of institutional knowledge and expertise has left the agency more vulnerable to political pressures and less capable of making informed decisions.

Makary's management style further contributed to this decline. He often sidelined staff who had a deep understanding of both the science and the regulatory process, instead favoring a more aggressive approach that prioritized quick "wins" over long-term benefits. This short-sighted strategy led to several questionable decisions, such as fast-tracking drugs with insufficient evidence of safety or efficacy.

While Makary did make some positive contributions-such as fostering the use of artificial intelligence in drug development and streamlining certain aspects of the review process-these efforts were overshadowed by his overall lack of strategic vision. The agency’s standards were weakened, and the trust it had built over decades was eroded.

What Comes Next

The resignation of Marty Makary under pressure marks a critical turning point for the FDA. As the search begins for a new commissioner, it is essential to address the structural and cultural issues that emerged during his tenure. The next leader must prioritize rebuilding trust, restoring high standards, and fostering a collaborative environment where expertise is valued.

One of the key challenges will be re-engaging with the scientific community and regaining the confidence of both industry stakeholders and the public. This will require transparent communication, a commitment to evidence-based decision-making, and a clear vision for the future of regulatory science.

The FDA plays a crucial role in ensuring that the medicines and devices we rely on are safe and effective. Makary’s legacy has left the agency in a vulnerable state, but with the right leadership, it can recover and continue to serve the public interest. The stakes are high, and the need for competent, ethical oversight has never been more urgent.

As we look ahead, the focus must be on finding a commissioner who understands the complexities of the FDA’s mission and is committed to upholding its highest standards. The health and well-being of millions depend on it.